Nine new causative mutations and seven previously characterised mutations of the APC gene of patients with familial adenomatous polyposis (FAP) were analysed for any genotype-phenotype correlations. The only clear genotype-phenotype correlation found was between the position of the mutation site and the presence or absence of congenital hypertrophy of the retinal pigment epithelium (CHRPE). A more distal mutation site was associated with an earlier age of onset of symptoms and a larger number of colonic polyps, but a notable amount ofintrafamilial variation was observed. In 1993, an FAP register was established in Wessex as a two year pilot project with regional funding. Following a systematic screen of the APC gene of 30 unrelated people with FAP from this register, we report nine new causative mutations plus seven previously characterised mutations. In order to study genotype-phenotype effects and any intrafamilial variation in expression, the position of the mutation site in the proband of each pedigree, and in any other available affected family members, was correlated to three phenotypic features: CHRPE status, age at diagnosis of polyps, and number of polyps.
Familial adenomatous polyposis (FAP)
Previous studies of genotype-phenotype correlations of APC mutations have shown a correlation between the position of the mutation site and one or more phenotypic features. The most commonly reported correlation is between the CHRPE status of patients and the site of the mutation, patients with a mutation in exons 1-9 being CHRPE negative while mutations 3' to exon 9 are associated with a CHRPE positive phenotype.8 11-14 All 12 of the patients with causative mutations who were examined in our study support this previously reported observation. The new mutations in exons 4 and 9 and the previously characterised exon 7 mutation result in a CHRPE negative phenotype while all the exon 15 mutations result in a CHRPE positive phenotype.
Past investigations into the correlation between the mutation site and disease severity have shown an association between the size of the truncated protein product and the number of colonic polyps with larger mutant proteins leading to a more severe phenotype, although significant interfamilial and intrafamilial variation has been reported in patients with an identical mutation.12 1>18 An explanation for larger mutant proteins leading to a more severe phenotype can be found from studies of the binding effects of truncated APC protein molecules. A larger mutant protein is more prone to dimerisation with a wild type protein than a more proximally truncated APC protein. Such dimerisation renders the wild type protein effectively inactive, thus reducing cellular levels of normal protein activity. "1 The data from our patients cannot support or refute this association owing to the small sample number and the difficulty of obtaining precise polyp counts retrospectively. However, the overall picture is consistent with this observation, and in families where accurate clinical information was available the expected pattern was followed. The 2 bp deletion in exon 9 seen in family W33 was associated with a low number of polyps in all four affected family members, whereas two of the exon 15 mutations (families W28 and W31) resulted in a manifestation of over 1000 polyps. For most families the clinical count of "hundreds of polyps" did not allow classification into high or low severity categories. Another problem when relating the numbers of polyps to the mutation site is that some patients, for example, the three affected members of family W20, were diagnosed at an early age and all had their colons removed. Had resection not taken place early, the number of polyps may have increased from hundreds to thousands, so these figures are not necessarily reflective ofthe severity ofthe phenotype. However, the detection of multiple polyps in these patients at such an early age is indicative of a more severe phenotype. Patient W6 and the three affected members of family W20 also suffer from the extracolonic manifestations described in classical Gardner's syndrome, while the dead mother of patient W41 had clinical evidence ofdesmoid disease; thus, other clinical factors may be of interest in genotype-phenotype correlations.
The third factor from our data to be related to the mutation site is the age at which polyps were first observed. Previously, a larger truncated protein product was reported to lead to an earlier age of onset, though quite a range of intrafamilial and interfamilial variation has been seen.'7 18 22-24 Such variation no doubt stems from the way in which tumour development is thought to occur. Although FAP patients have a constitutional mutation on one chromosome, the "two hit" theory describes the need for a second mutation to occur within the normal APC gene before a cell starts to proliferate.925 The timing of this second mutation will be subject to a wide range of external factors, such as natural carcinogens and diet, so variation in age of onset between people with the same mutation must be expected. In our studies, the age at which polyps were first observed was significantly higher (using Student's t test, p<0005) in patients with a mutation 5' to exon 10 (39 3 years) as compared to 25-1 years for patients with an exon 15 mutation. The age used in these calculations is the age at which the polyps were first seen during screening, but in many cases this was during the first ever bowel screen so polyps may well have developed many years before the examination. For these people, the age at which polyps were first seen may be considered inaccurate when attempting to relate these figures to the age of onset of symptoms. It can be counter-argued, however, that the reason these patients were not examined until a later age was because of the lack of symptoms, or later diagnosis in the closest affected relative (index case). The correlation may therefore still be valid. Considerable intrafamilial variation was seen, especially in families W13 and W29, so although an early age of onset (<20 years) may be solely associated with an exon 15 mutation in our study, a later age of onset (such as in patients W19, W29.1, and W21) is not necessarily indicative of a more proximal mutation site.
The lack of reliable clinical information (in particular accurate polyp counting) hampers this type ofstudy, as does inconsistent screening policies among surgeons. The establishment of regional registers for FAP will facilitate a more uniform approach to screening and follow up, allowing the collection of specific clinical data. With such data, clear conclusions may be drawn about genotype-phenotype correlations, which in turn will help to identify potential mutation sites. Of all the phenotypic manifestations, the CHRPE status of a person provides the most accurate and reliable evidence for the possible mutation site, though a severe phenotype with an early onset and thousands of polyps would be highly suggestive of a mutation in exon 15. With this in mind, the gathering of as many clinical details as possible before screening of the APC gene should allow a more rapid genetic confirmation of suspected FAP in future patients.
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